CR7622A - SEQUENCES OF THE CONTROL OF THE GENE OF HUMAN CORINA - Google Patents

SEQUENCES OF THE CONTROL OF THE GENE OF HUMAN CORINA

Info

Publication number
CR7622A
CR7622A CR7622A CR7622A CR7622A CR 7622 A CR7622 A CR 7622A CR 7622 A CR7622 A CR 7622A CR 7622 A CR7622 A CR 7622A CR 7622 A CR7622 A CR 7622A
Authority
CR
Costa Rica
Prior art keywords
corina
gene
control
sequences
human
Prior art date
Application number
CR7622A
Other languages
Spanish (es)
Inventor
Pan Junliang
Wu Quingyu
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of CR7622A publication Critical patent/CR7622A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

S e relaciona con el aislamiento , la clonacion, y la identificacion de las regiones de control de la expresion del gen de corina en mamiferos, incluyendo el promotor y otros elementos reguladores, y el uso de esta region de control de la expresion especifica del corazoon para indentificar nuevos agentes que modulan la expresion de gen de corina y para tratar enfermedades cardiacas.It is related to the isolation, cloning, and identification of the control regions of the expression of the corina gene in mammals, including the promoter and other regulatory elements, and the use of this control region of the specific expression of the heart to identify new agents that modulate the gene expression of corina and to treat heart disease.

CR7622A 2002-05-31 2004-12-15 SEQUENCES OF THE CONTROL OF THE GENE OF HUMAN CORINA CR7622A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38410802P 2002-05-31 2002-05-31

Publications (1)

Publication Number Publication Date
CR7622A true CR7622A (en) 2006-05-29

Family

ID=29711979

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7622A CR7622A (en) 2002-05-31 2004-12-15 SEQUENCES OF THE CONTROL OF THE GENE OF HUMAN CORINA

Country Status (18)

Country Link
US (1) US20030223976A1 (en)
EP (1) EP1546172A4 (en)
JP (1) JP2005531302A (en)
KR (1) KR20050009724A (en)
CN (1) CN1671729A (en)
AU (1) AU2003245342A1 (en)
BR (1) BR0311603A (en)
CA (1) CA2487024A1 (en)
CR (1) CR7622A (en)
EC (1) ECSP045518A (en)
IL (1) IL165244A0 (en)
MX (1) MXPA04011944A (en)
NO (1) NO20045722L (en)
PL (1) PL374125A1 (en)
RS (1) RS104404A (en)
RU (1) RU2004139055A (en)
WO (1) WO2003102135A2 (en)
ZA (1) ZA200410400B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026255A1 (en) * 2002-06-25 2005-02-03 Morser John Michael Corin, a serine protease
CN101061217A (en) * 2004-02-27 2007-10-24 通用医疗公司 Methods and compositions for hair growth
JP5680274B2 (en) 2005-12-01 2015-03-04 チバ ホールディング インコーポレーテッドＣｉｂａ Ｈｏｌｄｉｎｇ Ｉｎｃ． Oxime ester photoinitiator
US20110306069A1 (en) 2009-02-19 2011-12-15 Qingyu Wu Corin As A Marker For Heart Failure
CN105734070A (en) * 2016-04-11 2016-07-06 苏州大学 Corin gene variant and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917123A (en) * 1997-03-14 1999-06-29 University Of Pittsburgh Transgenic mice containing a nucleic acid encoding tumor necrosis factor-α under the control of a cardiac specific regulatory region
ATE397074T1 (en) * 1998-06-05 2008-06-15 Bayer Schering Pharma Ag CORIN, A SERINE PROTEASE
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
EP1252300B1 (en) * 2000-02-03 2011-01-19 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
AU2001243142A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2001245671A (en) * 2000-03-07 2001-09-11 Chiba Prefecture New gene cloned in human neuroblastoma and fragment thereof

Also Published As

Publication number Publication date
RU2004139055A (en) 2005-08-20
IL165244A0 (en) 2005-12-18
NO20045722L (en) 2004-12-30
AU2003245342A1 (en) 2003-12-19
CA2487024A1 (en) 2003-12-11
CN1671729A (en) 2005-09-21
WO2003102135A3 (en) 2004-11-04
RS104404A (en) 2006-12-15
US20030223976A1 (en) 2003-12-04
ZA200410400B (en) 2006-06-28
EP1546172A4 (en) 2005-11-30
WO2003102135A2 (en) 2003-12-11
BR0311603A (en) 2005-06-07
EP1546172A2 (en) 2005-06-29
MXPA04011944A (en) 2005-03-31
PL374125A1 (en) 2005-10-03
KR20050009724A (en) 2005-01-25
JP2005531302A (en) 2005-10-20
ECSP045518A (en) 2005-03-10

Similar Documents

Publication Publication Date Title
ECSP045520A (en) TREATMENT METHODS WITH PTEC INHIBITORS AND ANTIHIPERTENSIVE AGENTS
PA8804901A1 (en) RECEIVER INHIBITION FOR MACROFAGO STIMULATING PROTEIN (RON) AND METHODS FOR TREATMENT OF THE SAME
PE20181922A1 (en) GENE THERAPY TO TREAT HEMOPHILIA A
UY24805A1 (en) PEPTIDES AND COMPOUNDS THAT BIND TO THE THROMBOPOYETINE RECEPTOR
CL2011003346A1 (en) Compounds derived from 2,3-dihydro-5h- [1,3] thiazolo [3,2-a] pyrimidin-5-one, modulators of pi3k; pharmaceutical composition; and use to treat an immune-based disease, cancer, or lung disease in a patient.
CR7786A (en) NEUTRALIZING ANTIBODIES AGAINST GDF-8 AND THE USE OF THE SAME
CR9181A (en) ANTIANGIOGENESIS SELF-IMMUNITY THERAPY IN PATIENTS TO THOSE WHO PREVIOUS THERAPY FAILED
ATE453707T1 (en) METHOD FOR ISOLATION OF MESENCHYMAL STEM CELLS OF THE HAIR FOLLICLE
HK1096857A1 (en) Medicamentously targeted local lipolysis
AR010810A1 (en) COMPOSITION FOR THE PREPARATION OF LEATHER OR LEATHER, PROCESS FOR ITS PREPARATION AND A LEATHER OR LEATHER CONTAINING IT
BR112022007158A2 (en) IL-2 IMMUNOMODULATORY AGENTS IN COMBINATION WITH IMMUNOLOGICAL CHECKPOINT INHIBITORS
CR20220249A (en) Therapeutic derivatives of interleukin-22
CR7622A (en) SEQUENCES OF THE CONTROL OF THE GENE OF HUMAN CORINA
ES2196313T3 (en) USE OF INHIBITORS OF THE ACTIVITY OF THE RETINOIC ACID FOR THE TREATMENT OF SENSITIVE SKINS AND / OR THE ACUTE DAMAGES INDUCED BY UV RADIATIONS.
ATE337005T1 (en) NAIL POLISH CONTAINING TAZAROTENE AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF PSORIASIS
ATE552272T1 (en) MYOSTATIN ISOFORM
ES2165233T3 (en) USE OF 1-PHOSPHATE OF SPHINGOSINE, DERIVATIVES OF 1-PHOSPHATE OF SPHINGOSINE AND / OR ITS MIXTURES FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES.
AR126239A1 (en) REGION 5 UNTRANSLATED AND REGION 3 UNTRANSLATED NON-NATURAL AND USE OF THESE
ES2110057T3 (en) MEDICINAL COMPOSITION CONTAINING TCF-II.
AR039803A1 (en) PROTEINS 1 AND 2 RELATED TO THE LDL RECEPTOR AND TREATMENT OF BONE OR CARTILAGO DISORDERS
PT1276495E (en) USING RECOMBINANT PULMONARY TENSIONS FOR THE EARLY TREATMENT OF ACUTE PULMONARY DISEASES
GT199900167A (en) NEW BIS-BENZIMIDAZOLES.
ATE359088T1 (en) USE OF INTERLEUKIN-18 TO TREAT UV-ASSOCIATED SKIN DISEASES
ATE423780T1 (en) MACROCYCLES FOR THE TREATMENT OF CANCER DISEASES
BR0314364A (en) Use of iv pde inhibitors to treat angiogenesis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)